179 related articles for article (PubMed ID: 25424877)
41. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
[TBL] [Abstract][Full Text] [Related]
42. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
43. CAP1 is overexpressed in human epithelial ovarian cancer and promotes cell proliferation.
Hua M; Yan S; Deng Y; Xi Q; Liu R; Yang S; Liu J; Tang C; Wang Y; Zhong J
Int J Mol Med; 2015 Apr; 35(4):941-9. PubMed ID: 25652936
[TBL] [Abstract][Full Text] [Related]
44. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
45. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.
Wang X; Meng X; Li H; Liu W; Shen S; Gao Z
Clin Transl Oncol; 2014 Nov; 16(11):954-8. PubMed ID: 24696291
[TBL] [Abstract][Full Text] [Related]
47. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
48. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
Xie X; Yang M; Ding Y; Yu L; Chen J
Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer.
Lv Q; Sun H; Cao C; Gao B; Qi Y
Tumour Biol; 2016 Feb; 37(2):2721-7. PubMed ID: 26408177
[TBL] [Abstract][Full Text] [Related]
50. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
[TBL] [Abstract][Full Text] [Related]
51. RECQL1 plays an important role in the development of tongue squamous cell carcinoma.
Tao J; Tao S; Han J; Zhou Z; Zhang X; Wang H; Chen R; Ji F; Zhu Y
Cell Physiol Biochem; 2014; 33(5):1579-90. PubMed ID: 24854846
[TBL] [Abstract][Full Text] [Related]
52. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
54. Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer.
Fan X; Wang C; Song X; Liu H; Li X; Zhang Y
Histol Histopathol; 2018 Jul; 33(7):673-680. PubMed ID: 29303207
[TBL] [Abstract][Full Text] [Related]
55. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
57. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
[TBL] [Abstract][Full Text] [Related]
59. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
60. Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.
Guo F; Feng L; Hu JL; Wang ML; Luo P; Zhong XM; Deng AM
Tumour Biol; 2015 Jan; 36(1):453-8. PubMed ID: 25270739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
